Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

In anorexia nervosa (AN), medical stabilization and nutritional repletion are pivotal steps toward physical and psychological recovery.

Nutritional stabilization is often difficult in this patient group.

The researchers hypothesize that rhGH treatment will hasten medical stabilization in AN patients.

Who Took Part

By PubMed's age tags, the people studied were children and teenagers, both men and women.

Fifteen patients admitted for inpatient treatment for AN, ages 12-18 years, were enrolled in a 28-day randomized, double-blind, placebo-controlled study.

All patients received a standard refeeding protocol.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

Outcome measures included time to reach medical/cardiovascular stability, rate of weight gain, and duration of hospitalization.

What Was Measured

The subject headings attached to it are Anorexia Nervosa, Body Mass Index, Hormone Replacement Therapy, Human Growth Hormone, Length of Stay, Pilot Projects and Weight Gain.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Journal of child and adolescent psychopharmacology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.